Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | GALR1 | P47211 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149013 | 0.91 | DRD3 (0.44) | DRD3HRH3MAPK1 | |
| SCHEMBL4149102 | 0.86 | ALOX5 (0.44) | ALOX5DRD3GALR1ATMDPP4 | |
| SCHEMBL4136466 | 0.86 | PDE4A (0.43) | HRH3LMNA | |
| SCHEMBL3324704 | 0.85 | TDP2 (0.41) | DPP4HRH3LMNA | |
| SCHEMBL3324698 | 0.85 | TDP2 (0.41) | DPP4HRH3LMNA | |
| SCHEMBL3323263 | 0.85 | TDP2 (0.41) | DPP4HRH3LMNA | |
| SCHEMBL4142054 | 0.81 | HRH3 (0.49) | DRD3HRH3LMNA | |
| SCHEMBL4135775 | 0.81 | HTR2C (0.41) | DRD3HRH3LMNA | |
| SCHEMBL4141100 | 0.81 | HRH3 (0.38) | HRH3LMNA | |
| SCHEMBL4135773 | 0.80 | CYP11B1 (0.37) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | ALOX5 2512/4885DRD3 167/4885GALR1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.